Mercurna Expands to New Laboratory at BioMatTech Campus in Nijmegen

To support its expanding ambitions, Mercurna, a pre-clinical-stage biotechnology company developing a platform for life-changing medicines based on messenger RNA (mRNA), has moved into a new, larger laboratory at the BioMatTech Campus in Nijmegen.

1 November 2024

To support its growing ambitions, Mercurna, a pre-clinical-stage biotechnology company developing a platform for life-changing medicines based on messenger RNA (mRNA), has moved into a new, larger laboratory at the BioMatTech Campus in Nijmegen.

The laboratory is equipped with all infrastructure to further develop Mercura's proprietary platform technology for mRNA-based medicines and advance the development of multiple lead-formulations based on the platform. Mercurna’s lead therapeutic candidate mCura1 is advancing toward the treatment of inflammatory kidney disease, supported by strong preclinical proof‑of‑concept results.

Being strategically positioned in Nijmegen enables close collaboration with key partners at Radboudumc, as well as access to their state‑of‑the‑art research facilities. In addition to its Nijmegen base, Mercurna maintains an important presence in Oss, reflecting its ongoing collaborations with major players across the biotech value chain.

"We are very happy that the BioMatTech Campus provides us with laboratory and office space solutions tailored to our needs and in addition provides us with a perspective for further expansion in the future", says Jenny van Asbeck, CEO of Mercuma.